Claims for Patent: 4,579,855

Summary for Patent: 4,579,855

Title:	Melfloquin hydrochloride
Abstract:	Mefloquin hydrochloride in the form of modification E as characterized by IR spectrum and X-ray diffraction pattern, as well as a process for the preparation thereof by treating mefloquin hydrochloride, comprising at least partially another modification, that is, mefloquin hydrochloride which is not pure mefloquin hydrochloride in the form of modification E, with methanol and/or ethanol, in the presence of less than 30 volume/percent of water.
Inventor(s):	Bomches; Helmut (Aesch, CH), Hardegger; Bruno (Riehen, CH)
Assignee:	Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:	06/655,813
Patent Claims:	1. Essentially pure erythro-.alpha.-2-piperidyl-2,8-bis-(trifluoromethyl)-4-quinolinemethanol hydrochloride in the form of its modification E. 2. Essentially pure erythro-.alpha.-2-piperidyl-2,8-bis-(trifluoromethyl)-4-quinolinemethanol hydrochloride in the form of its modification E characterized by the IR spectrum, FIG. 5, and/or the X-ray diffraction pattern and/or the d-values, FIG. 6. 3. A non-liquid, dry pharmaceutical composition comprising an antimalarially effective amount of essentially pure mefloquin hydrochloride in the form of its modification E and an inert carrier material. 4. A non-liquid, dry pharmaceutical composition, in accordance with claim 3, which contains pyrimethamine and sulfadoxine in addition to the essentially pure mefloquin hydrochloride in the form of its modification E in an antimalarially effective amount. 5. A method of treating or preventing all forms of malaria in a host in need of such treatment which comprises administering to said host a pharmaceutical composition containing an antimalarially effective amount of essentially pure mefloquin hydrochloride in the form of its modification E alone or in combination with other therapeutically active substances. 6. A method of treating or preventing all forms of malaria in a host in need of such treatment which comprises administering to said host a pharmaceutical composition containing an antimalarially effective amount of a combination of essentially pure mefloquin hydrochloride in the form of its modification E, sulfadoxine and pyrimethamine.